FDA Expands Afatinib’s Approval for Lung Cancer

January 14, 2018 – The FDA has expanded the frontline indication for afatinib to include the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor uncommon EGFR alterations in L861Q, G719X, and/or S768I. The approval for uncommon, non-resistance EGFR mutations was based on findings from 32 patients in the phase II LUX-Lung 2 trial (LL2) and the randomized phase III trials known as LUX-Lung 3 (LL3) and … (leggi tutto)